RxDoctor Payments Data

Leo Tynan, MD

Internal Medicine · Fredericksburg, TXNPI 1811937303

Payments from drug & device makers

$1,169in general payments, 2019–2025

Across 68 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$543
  • Astellas Pharma US Inc$128
  • Johnson & Johnson$121
  • GSK$93
  • Amarin Pharma, Inc.$64
  • AbbVie$50
  • plus $170 from 9 others

What the payments were for

  • Food & beverage$1,09494%
  • Education$756%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,169 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$176,254
Medicare patients
208
Services billed
3,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$57,195
EliquisApixaban55$36,494
MounjaroTirzepatide15$25,092
TrulicityDulaglutide18$24,345
XareltoRivaroxaban28$23,986
JardianceEmpagliflozin21$22,771
MyrbetriqMirabegron20$15,909
Repatha SureclickEvolocumab22$12,001
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,796
Breo ElliptaFluticasone/Vilanterol14$7,293
Nebivolol Hcl60$3,272
LumiganBimatoprost11$2,967
Ezetimibe50$2,956
PaxlovidNirmatrelvir/Ritonavir27$2,796
Telmisartan82$2,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$57,19556 claims
Johnson & JohnsonXarelto$121$23,98628 claims
Boehringer IngelheimJardiance$16$22,77121 claims
Astellas Pharma US IncMyrbetriq$128$15,90920 claims
GSKTrelegy Ellipta, Breo Ellipta$93$15,08926 claims
AbbVieLumigan, Synthroid$50$3,93240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Fredericksburg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →